NeoGenomics - Stock Price History | NEO

Historical daily share price chart and data for NeoGenomics since 2021 adjusted for splits. The latest closing stock price for NeoGenomics as of September 23, 2021 is 49.94.
  • The all-time high NeoGenomics stock closing price was 59.88 on February 12, 2021.
  • The NeoGenomics 52-week high stock price is 61.57, which is 23.3% above the current share price.
  • The NeoGenomics 52-week low stock price is 35.74, which is 28.4% below the current share price.
  • The average NeoGenomics stock price for the last 52 weeks is 46.78.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
NeoGenomics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 35.0760 29.0500 56.4700 20.5000 53.8400 84.07%
2019 21.6975 12.5400 29.8400 12.1400 29.2500 131.96%
2018 11.9847 8.7200 18.5000 7.2300 12.6100 42.33%
2017 8.7618 8.6300 11.2600 7.2400 8.8600 3.38%
2016 7.9009 7.5600 9.7900 5.5700 8.5700 8.89%
2015 5.7739 4.0900 8.2500 3.5600 7.8700 88.73%
2014 4.2094 3.6900 5.9900 3.0300 4.1700 15.19%
2013 3.3137 2.6500 4.1700 2.1000 3.6200 45.97%
2012 2.1043 1.4200 3.1000 1.4000 2.4800 77.14%
2011 1.3413 1.2400 1.5600 1.0100 1.4000 7.69%
2010 1.2535 1.5000 1.5700 1.0000 1.3000 -13.33%
2009 1.3186 0.6400 2.1000 0.6200 1.5000 145.90%
2008 0.9422 1.0500 1.3000 0.5600 0.6100 -43.52%
2007 1.4680 1.6100 1.8600 1.0400 1.0800 -28.00%
2006 0.8081 0.1920 2.0100 0.1250 1.5000 689.47%
2005 0.3823 0.2500 0.6500 0.1900 0.1900 -24.00%
2004 0.3180 0.4300 0.8500 0.1800 0.2500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.163B $0.444B
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71